课题基金 / 基金详情

Small-molecule probes of chromatin-mediated neuroplasticity

Small-molecule probes of chromatin-mediated neuroplasticity
染色质介导的神经可塑性的小分子探针
批准号:
8534080
负责人:
STEPHEN J HAGGARTY
金额:
$56.19万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-01 至 2015-08-31

项目摘要

项目成果

STEPHEN J HAGGARTY的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Advancing our understanding of neuroplasticity and the development of novel therapeutics based upon this knowledge is critical in order to improve the treatment and prevention of nervous system disorders. Recent molecular, cellular, and behavioral findings have revealed the importance of epigenetic mechanisms that alter chromatin structure in maintaining stable patterns of gene expression and altering neuroplasticity associated with mood and memory formation. However, the dynamic and combinatorial nature of these signaling events has meant that the state of our understanding and ability to manipulate the underlying molecular mechanisms in the nervous system remains limited. To overcome these limitations, the long-term goals of the studies outlined in this proposal are to systematically develop selective, brain-penetrant, small-molecule probes (SMPs) of chromatin-remodeling complexes that affect neural activity-regulated gene transcription. Our overall hypothesis is that by selectively targeting the enzymatic activity of specific members of the histone deacetylase (HDAC) and histone acetyltransferase (HAT) families that it will be possible manipulate the acetylation state of histones in the promoters of certain immediate early genes (IEGs) thereby affecting neural- activity-regulated gene transcription and neuroplasticity. To develop the methods and SMPs necessary to rigorously test this hypothesis the proposed studies will address the following aims. In Aim I, the structure- activity-relationships of two types of SMPs that enhance cAMP response element (CRE)-mediated transcription through affecting the activity of certain HDAC and HAT isoforms will be determined. As a sub-aim, proteomic profiling using affinity probes will be used to determine the components of the chromatin-remodeling complexes targeted by both types of SMPs. In Aim II, a real time, automated microscopy-based imaging assay of cultured neurons from bacterial artificial chromosome (BAC)-transgenic mice expressing a genetically encoded fluorescent reporter of IEG expression, will be developed. As a sub-aim, this assay will be used in combination with immunofluorescent detection of histone-modifications to characterize the effect of manipulating HDAC/HAT-complex activities on IEG expression using SMPs and RNAi-mediated gene silencing. In Aim III, the effect of specific HDAC inhibitors and HAT activators in mouse behavioral tests of hippocampal-dependent memory and depression-like behavior will be determined along with measurements of corresponding changes in brain gene expression patterns and histone acetylation. Significance: We anticipate these multidisciplinary studies will shed new light on molecular mechanisms of neuroplasticity and the relevance of these mechanisms to the development of novel therapeutics for memory and mood disorders. PUBLIC HEALTH RELEVANCE: Advancing our understanding of brain plasticity and the development of novel therapeutics based upon this knowledge is critical in order to improve the treatment and prevention of a myriad of central nervous system disorders. This work will characterize the role that gene expression plains in mediating aspects of brain plasticity relevant to mood and memory disorders using small molecules as probes in biochemical and mouse behavioral studies. These multidisciplinary studies will shed new light on molecular mechanisms of brain plasticity and the relevance of these mechanisms to the development of novel therapeutics for their treatment of memory and mood disorders.
期刊论文(11)
专著(0)
科研奖励(0)
会议论文
Kinetically Selective Inhibitors of Histone Deacetylase 2 (HDAC2) as Cognition Enhancers.
组蛋白脱乙酰酶 2 (HDAC2) 的动力学选择性抑制剂作为认知增强剂
DOI: 10.1039/c4sc02130d
发表时间: 2015-01-01
期刊: Chemical science
影响因子: 8.4
作者: [Wagner FF, Zhang YL, Fass DM, Joseph N, Gale JP, Weïwer M, McCarren P, Fisher SL, Kaya T, Zhao WN, Reis SA, Hennig KM, Thomas M, Lemercier BC, Lewis MC, Guan JS, Moyer MP, Scolnick E, Haggarty SJ, Tsai LH, Holson EB]
通讯作者: Holson EB
An epigenetic blockade of cognitive functions in the neurodegenerating brain.
神经退行性大脑中认知功能的表观遗传封锁
DOI: 10.1038/nature10849
发表时间: 2012-02-29
期刊: NATURE
影响因子: 64.8
作者: [Graeff, Johannes, Rei, Damien, Guan, Ji-Song, Wang, Wen-Yuan, Seo, Jinsoo, Hennig, Krista M., Nieland, Thomas J. F., Fass, Daniel M., Kao, Patricia F., Kahn, Martin, Su, Susan C., Samiei, Alireza, Joseph, Nadine, Haggarty, Stephen J., Delalle, Ivana, Tsai, Li-Huei]
通讯作者: Tsai, Li-Huei
DOI: 10.1371/journal.pone.0071323
发表时间: 2013
期刊: PloS one
影响因子: 3.7
作者: [Schroeder FA, Lewis MC, Fass DM, Wagner FF, Zhang YL, Hennig KM, Gale J, Zhao WN, Reis S, Barker DD, Berry-Scott E, Kim SW, Clore EL, Hooker JM, Holson EB, Haggarty SJ, Petryshen TL]
通讯作者: Petryshen TL
DOI: 10.1016/j.cell.2013.12.020
发表时间: 2014-01-16
期刊: Cell
影响因子: 64.5
作者: [Gräff J, Joseph NF, Horn ME, Samiei A, Meng J, Seo J, Rei D, Bero AW, Phan TX, Wagner F, Holson E, Xu J, Sun J, Neve RL, Mach RH, Haggarty SJ, Tsai LH]
通讯作者: Tsai LH
9
    Tuberous Sclerosis Complex Patients iPSC-derived NPCs and NCCs as Human Model Systems to Identify Novel Targets
    • 批准号:
      10408151
    • 项目类别:
    • 资助金额:
      $48.69万
    • 财政年份:
      2019
    • 负责人:
      STEPHEN J HAGGARTY
    • 依托单位:
    Tuberous Sclerosis Complex Patients iPSC-derived NPCs and NCCs as Human Model Systems to Identify Novel Targets
    • 批准号:
      10641016
    • 项目类别:
    • 资助金额:
      $48.69万
    • 财政年份:
      2019
    • 负责人:
      STEPHEN J HAGGARTY
    • 依托单位:
    Validation of Modulators of PGRN as Novel Therapeutics for Frontotemporal Dementi
    • 批准号:
      9674183
    • 项目类别:
    • 资助金额:
      $81.48万
    • 财政年份:
      2018
    • 负责人:
      STEPHEN J HAGGARTY
    • 依托单位:
    Validation of Modulators of PGRN as Novel Therapeutics for Frontotemporal Dementi
    • 批准号:
      10480905
    • 项目类别:
    • 资助金额:
      $80.09万
    • 财政年份:
      2018
    • 负责人:
      STEPHEN J HAGGARTY
    • 依托单位:
    海外基金